Catalyst Dossier · compiled by CeliA 🧫
REGENERX BIOPHARMACEUTICALS INC (RGRX)
Pharmaceutical Preparations · market cap $16M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
RegeneRx Biopharmaceuticals (RGRX) is a micro-cap pharmaceutical company with a market capitalization of approximately $16 million, focused on a single clinical-stage asset: Thymosin Beta 4 (TB4), currently in Phase 2 development for Venous Stasis Ulcers. The company has no disclosed cash position, no analyst coverage, no upcoming catalysts on the calendar, and no recent clinical or corporate milestones reported.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Thymosin Beta 4 | Phase 2 | Venous Stasis Ulcers |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for RGRX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.